FDA’s Neoadjuvant Breast Cancer Accelerated Approval Pathway Starts To Take Shape
Executive Summary
The agency is stressing that its new neoadjuvant pathway is intended for areas of high unmet need and won’t become the path of least resistance for pharma. But it is also signaling openness for testing drugs aimed at women with HER2-positive disease, who have a better prognosis and treatment options.